SMS Pharmaceuticals Ltd.
Snapshot View

176.05 -1.85 ▼-1.0%

30 July 2021, 04:00:00 P.M.
Volume: 10,284

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.smspharma.com
Financial Indicators
Market Cap 1,483.53 Cr.
Earnings per share (EPS) 7.39 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 23.73 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 48.50 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.61 Calculated using Price: 175.25
Dividend Yield 0.14 Period Ending 2020-03
No. of Shares Subscribed 8.47 Cr. 84,652,030 Shares
FaceValue 1
Company Profile

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. What started off as a single facility single product manufacturing company in 1990 grew to be a multi location group having product list spreading across an array of therapeutic segments. SMS is currently a listed company having ever appreciating international and domestic customer base. Having six multi product facilities in operation, one under development, and two research centers, SMS has truly graduated in to big league with more than 600 employees working for it.

SMS Pharmaceuticals is an integrated pharma company with business presence in over 70 countries.

SMS is focused on API manufacturing and is the single largest producer of anti ulcer products and is renowned among the clientele for the excellent quality of product and customer service.

The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

SMS is venturing into highly specialized oncology segment by building first of its kind dedicated oncology API and formulations manufacturing facility in Andhra Pradesh to target the niche market segments.

Merger of Sreenivasa Pharma Private Ltd with SMS Pharmaceuticals Ltd has given a new boost to the company, SMS Pharma has also completed the takeover of Plant Organics.

Recently SMS has established new state of art corporate research center with ultramodern facilities encompassing the whole gamut of research activity viz. from product conception to development, scaling up and DMF preparation. This is supported by well equipped analytical wing and a fully functional pilot plant. This new facility will enhance our existing offerings from a contract research and custom synthesis point of view.

R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.

SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.

Product range of the company includes:

  • API and Intermediates
  • Cytotoxic Solid Dose, Sterile Cytotoxic Liquid, and Lyophilized Products
  • Bio Products
  • Inorganic Products
  • Nutraceuticals

Different divisions of the company:

  • Manufacturing :SMS Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturing companies in India with world-class facilities with a wide range of process equipment fully compliant with WHO GMP standards.SMS has over the years developed tremendous manufacturing facilities to suit its style of operations and to meet the requirements of USFDA and other regulatory markets. A total of 6 facilities are being presently operated and one is under construction.
  • Research and development :R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.SMS research team now comprises of about 100 scientists with expertise in process research, analytical research and scale up. A dedicated project management team handles costing, administration, purchase, and project monitoring. R&D capabilities of the company span across reaction technologies, organic compound categories, and novel catalytic systems. This center is capable of delivering top notch contract research modules to international clientele.

Achievements/ recognition :

  • SMS was given the export house status in the year 1997-98.
  • Awarded the Prestigious ' Pandit Jawaharlal Nehru Silver Rolling Trophy' for the best productivity effort in the state.
  • Became the single largest producer of Ranitidine Hydrochloride in the World.
  • One of the leading export houses exporting to more than 70 countries worldwide.
  • WHO-GMP approved API manufacturing facilities in India (2 more to be operational soon).
  • Achieved ISO 9001 certification for Units at Khazipally and Bollaram.
  • Awarded the prestigious US GCNC Green chemistry award.
  • Successfull FDA audits in 2004 and 2008 at our Bachupally unit.
  • Proven expertise in low cost process routes, commercialization & manufacturing.
  • Over 21 process patents and 72 regulatory filings.
  • Successful execution of contract research and manufacturing assignments.
  • CRISIL renews SMS Pharma's SME 1 rating for FY 09-10.
  • Recieved 'Best Industrial Productivity Effort in the State' silver rolling trophy.

Future plan:

SMS is building an ultra modern API manufacturing facility near Vizag on the eastern coast of India to cater to in house production needs and also for the emerging contract manufacturing business.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.04%
1 Week
-5.88%
1 Month
+1.59%
3 Month
+17.02%
6 Month
+52.42%
1 Year
+131.19%
2 Year
+260.02%
5 Year
+84.06%
5 years 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 17.57 12.99 15.00 13.67 9.76
Return on Capital Employed (%) 19.54 12.73 18.17 16.57 13.06
Return on Assets (%) 8.46 6.15 7.95 7.62 5.50

Balance Sheet View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 294 255 284 322 348
Non Curr. Liab. 162 91 97 94 114
Curr. Liab. 200 156 134 156 154
Minority Int.
Equity & Liab. 656 502 515 572 617
Non Curr. Assets 408 336 334 351 389
Curr. Assets 248 166 181 221 228
Misc. Exp. not W/O
Total Assets 656 502 515 572 617

Profit Loss View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 612 445 465 465 412
Other Income 4 1 2 3 5
Total Income 615 447 467 468 417
Total Expenditure -522 -370 -372 -375 -332
PBIDT 93 77 96 94 85
Interest -17 -16 -15 -12 -12
Depreciation -19 -19 -20 -19 -22
Taxation -15 -6 -20 -21 -18
Exceptional Items
PAT 42 36 40 41 33

Cash Flow View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 61 73 32 50 40
Cash Fr. Inv. -97 -39 -17 -35 -43
Cash Fr. Finan. 44 -33 -15 -13 -2
Net Change 9 1 0 2 -5
Cash & Cash Eqvt 11 12 13 15 10

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 67.27 67.29 67.29 68.69 67.29 67.29 67.29 67.29 67.29
Public 32.73 32.71 32.71 31.31 32.71 32.71 32.71 32.71 32.71
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 11.12 11.11 8.83 8.28 8.83 8.83 10.24 10.24 0.00

Announcements View Details

Fri, 09 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Ramesh Babu Potluri
Designation :- Managing Director / Whole Time Director
Fri, 09 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30th June 2021

In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 we are forwarding herewith a copy of the Certificate dated 7th July 2021 received from Aarthi Consultants Private Limited Hyderabad the Registrar and Share Transfer Agent of the Company for the quarter ended 30th June 2021.
Thu, 08 Jul 2021
Shareholding for the Period Ended June 30 2021
SMS Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
5 EMA Crossing 20 EMA From Above 5 EMA Crossing 20 EMA From Above
+DI Crossing -DI From Above +DI Crossing -DI From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%